Clinical Trials Logo

Clinical Trial Summary

The current study aimed to determine the incidence of hypophosphatemia (HP) among severe sepsis/septic shock patients admitted to ICU and its impact on morbidity and mortality rates of these patients, and to evaluate the impact of phosphorous supplemental therapy (PST) on such outcomes.Thus, this study will hypothesize that diagnosis and management of HP may be advantageous for reduction of morbidity and mortality rates of septic patients admitted to ICU.


Clinical Trial Description

The study will include all patients admitted to ICU with or developing severe sepsis or septic shock within 24-hr after admission to ICU. Patients will be categorized according to at-admission inorganic phosphate (Pi) level into normophosphatemia group and hypophosphatemia group (HP) (mild, moderate and severe HP). All patients will be evaluated using Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II score (APACHE II) and blood samples will be collected for ELISA estimation of serum Pi, human C-reactive protein (CRP), L-lactate, CBC picture , serum electrolytes and kidney and liver function tests. Serum Pi level will be re-estimated immediately and 24-hr after full dose administration. Outcomes will include the 28-day ICU morbidity and mortality rates and their relation to HP severity and PST administration.

Patients who will fulfill the inclusion criteria will be selectively divided into two groups according to estimated level of serum Pi: Control group will include patients with serum Pi >2.5 mg/dl and Study group will include patients having serum Pi<2.5 mg/dl and will be further sub-grouped according to severity of HP into mild HP (2-2.5 mg/dl), moderate (1-1.9 mg/dl) or severe (<1 mg/dl).

Central venous catheter will be inserted for all patients enrolled in the study via the jugular or subclavian vein. Then, baseline hemodynamic parameters and central venous pressure (CVP) will be estimated and will be continuously monitored. Arterial blood samples will be obtained anaerobically and collected in heparinized tubes for estimation of arterial blood gas and pH.

Sepsis management: Patients were managed according to guidelines of Surviving

Sepsis Campaign; briefly:

1. Fluid therapy

2. Vasoactive drug therapy

3. Intropics

4. Antibiotic therapy

HP management regimen follows:

1. Calculation of supplementation dose according to the equation: phosphate dose (in mmol) = 0.5 x body weight x (1.25 - [serum Pi]).

2. Preparation that will be used: Glycophos®, Fresenius Kabi Egypt (organic phosphate solution 1mmol/ml). Vial 20 ml (1ml contains 1mmol of phosphate and 2mmol of sodium).

3. Dilution: will be diluted prior to parenteral administration. 20 ml of sodium-glycerophosphate diluted in 30 cc of dextrose 5% administered by syringe pump (50 mL).

4. The total calculated dose will be divided into three doses every 8 hours. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04519762
Study type Interventional
Source Ain Shams University
Contact Noha Hussien, Dr.
Phone +201222830981
Email nohasayedhussien@gmail.com
Status Not yet recruiting
Phase Phase 4
Start date September 15, 2020
Completion date December 15, 2020

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04502784 - Investigation of Hypophosphataemia Following Intravenous Iron
Completed NCT03529058 - Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU
Terminated NCT01011114 - Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant N/A
Completed NCT05098249 - Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia Phase 4
Not yet recruiting NCT06350955 - IV Iron-induced Hypophosphatemia After RYGB Phase 4
Completed NCT00688077 - FGF-23 Suppressibility by Calcitonin N/A
Recruiting NCT04814641 - Hypophosphatemia and Bronchiolitis
Recruiting NCT01660308 - Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia N/A
Active, not recruiting NCT03976440 - Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study
Recruiting NCT05909722 - Validation of the GIDS and Description of Phosphate Disorders
Completed NCT03581591 - Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets Phase 3
Completed NCT03740802 - Hypophosphatemia as a Predictor in Surgical Resuscitation Sepsis
Suspended NCT03771105 - The Impact of Phosphate Metabolism on Healthy Aging Early Phase 1
Active, not recruiting NCT06112236 - Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia
Completed NCT03489993 - FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
Completed NCT00975000 - Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Phase 3
Withdrawn NCT02837523 - Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
Not yet recruiting NCT06344546 - Metabolic Pathway Analysis in Intensive Care Unit Patients With Refeeding Syndrome